Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BDSX NASDAQ:EUDA NASDAQ:NAKA NASDAQ:XGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBDSXBiodesix$15.77+6.5%$13.98$5.00▼$20.21$163.38M0.43912,847 shs56,336 shsEUDAEUDA Health$18.38+1.6%$11.22$5.26▼$86.00$46.22M0.5682,480 shs9,027 shsNAKAKindlyMD$5.39-0.2%$8.31$4.50▼$995.60$93.80M17.12160,101 shs699,964 shsXGNExagen$5.11+2.0%$3.21$2.59▼$12.23$123.24M1.81452,803 shs249,312 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBDSXBiodesix0.00%+3.06%+46.20%+4.15%+113.77%EUDAEUDA Health+0.44%+0.44%+40.59%-0.45%-74.96%NAKAKindlyMD-1.64%-14.50%-30.66%-48.28%+539,999,900.00%XGNExagen+8.44%+30.81%+82.85%+31.84%-26.43%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBDSXBiodesix$15.77+6.5%$13.98$5.00▼$20.21$163.38M0.43912,847 shs56,336 shsEUDAEUDA Health$18.38+1.6%$11.22$5.26▼$86.00$46.22M0.5682,480 shs9,027 shsNAKAKindlyMD$5.39-0.2%$8.31$4.50▼$995.60$93.80M17.12160,101 shs699,964 shsXGNExagen$5.11+2.0%$3.21$2.59▼$12.23$123.24M1.81452,803 shs249,312 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBDSXBiodesix0.00%+3.06%+46.20%+4.15%+113.77%EUDAEUDA Health+0.44%+0.44%+40.59%-0.45%-74.96%NAKAKindlyMD-1.64%-14.50%-30.66%-48.28%+539,999,900.00%XGNExagen+8.44%+30.81%+82.85%+31.84%-26.43%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBDSXBiodesix 2.33Hold$22.0039.51% UpsideEUDAEUDA Health 2.00Hold$55.00199.30% UpsideNAKAKindlyMD 2.40Hold$30.00456.59% UpsideXGNExagen 2.78Moderate Buy$9.2581.09% UpsideCurrent Analyst Ratings BreakdownLatest EUDA, BDSX, NAKA, and XGN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/18/2026BDSXBiodesix Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/12/2026XGNExagen Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/12/2026XGNExagen BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$9.00 ➝ $8.005/11/2026NAKAKindlyMD Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/8/2026EUDAEUDA Health Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D) ➝ Sell (E+)5/8/2026EUDAEUDA Health Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold5/5/2026BDSXBiodesix Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$20.00 ➝ $22.005/4/2026BDSXBiodesix Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/27/2026XGNExagen Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)4/20/2026XGNExagen Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$10.00 ➝ $8.004/10/2026NAKAKindlyMD TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$40.00(Data available from 5/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBDSXBiodesix$88.50M1.85N/AN/A$0.88 per share17.92EUDAEUDA Health$6.82M6.78N/AN/A($2.26) per share-8.13NAKAKindlyMD$3.92M23.93N/AN/A$21.09 per share0.26XGNExagen$66.57M1.85N/AN/A$0.60 per share8.51Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBDSXBiodesix-$35.26M-$4.06N/AN/AN/A-33.26%-2,101.40%-35.65%8/6/2026 (Estimated)EUDAEUDA Health-$2.77M-$2.40N/AN/AN/AN/AN/AN/A7/28/2026 (Estimated)NAKAKindlyMD-$52.23M-$43.20N/AN/AN/A-7,397.12%-81.32%-54.17%N/AXGNExagen-$19.95M-$0.89N/AN/AN/A-29.49%-94.37%-28.96%8/4/2026 (Estimated)Latest EUDA, BDSX, NAKA, and XGN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026NAKAKindlyMDN/A-$15.20N/A-$0.38N/A$2.68 million5/11/2026Q1 2026XGNExagen-$0.24-$0.17+$0.07-$0.17$16.41 million$17.31 million5/5/2026Q4 2025EUDAEUDA Health-$1.20-$0.44+$0.76-$0.44$3.90 million$1.92 million5/4/2026Q1 2026BDSXBiodesix-$1.1298-$0.81+$0.3198-$0.81$23.12 million$25.56 million3/10/2026Q4 2025XGNExagen-$0.20-$0.20N/A-$0.20$16.46 million$16.63 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBDSXBiodesixN/AN/AN/AN/AN/AEUDAEUDA HealthN/AN/AN/AN/AN/ANAKAKindlyMDN/AN/AN/AN/AN/AXGNExagenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBDSXBiodesix5.092.822.82EUDAEUDA HealthN/A0.180.18NAKAKindlyMDN/A0.250.25XGNExagen1.673.473.47Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBDSXBiodesix20.96%EUDAEUDA Health4.35%NAKAKindlyMDN/AXGNExagen75.25%Insider OwnershipCompanyInsider OwnershipBDSXBiodesix23.20%EUDAEUDA HealthN/ANAKAKindlyMD24.49%XGNExagen12.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBDSXBiodesix22010.36 million7.95 millionNo DataEUDAEUDA Health22.52 millionN/ANot OptionableNAKAKindlyMDN/A17.40 million13.14 millionN/AXGNExagen22024.16 million21.12 millionOptionableEUDA, BDSX, NAKA, and XGN HeadlinesRecent News About These CompaniesHow Much Upside is Left in Exagen (XGN)? Wall Street Analysts Think 73.05%2 hours ago | zacks.comExagen Inc. (NASDAQ:XGN) Given Consensus Recommendation of "Moderate Buy" by AnalystsMay 19, 2026 | americanbankingnews.comExagen Earnings Call Highlights Growth Amid Key RisksMay 15, 2026 | theglobeandmail.comThe Exagen Inc. (NASDAQ:XGN) First-Quarter Results Are Out And Analysts Have Published New ForecastsMay 15, 2026 | finance.yahoo.comExagen Inc. (NASDAQ:XGN) Q1 2026 Earnings Call TranscriptMay 13, 2026 | insidermonkey.comExagen Inc (XGN) Q1 2026 Earnings Call Highlights: Record Revenue and Strategic Growth Amid ...May 12, 2026 | finance.yahoo.comExagen Inc. (XGN) Q1 2026 Earnings Call TranscriptMay 12, 2026 | seekingalpha.comRecord revenue growth and higher test pricing keep Exagen (XGN) in focus despite ongoing lossesMay 12, 2026 | msn.comExagen Q1 Earnings Call HighlightsMay 11, 2026 | marketbeat.comExagen (NASDAQ:XGN) Issues Earnings Results, Beats Estimates By $0.07 EPSMay 11, 2026 | marketbeat.comExagen Inc. (XGN) Reports Q1 Loss, Beats Revenue EstimatesMay 11, 2026 | zacks.comExagen Inc. Reports First Quarter 2026 ResultsMay 11, 2026 | globenewswire.comExagen (NASDAQ:XGN) Upgraded by Wall Street Zen to "Hold" RatingMay 9, 2026 | marketbeat.comZimmer Biomet (ZBH) Q1 Earnings and Revenues Top EstimatesApril 28, 2026 | zacks.comExagen Inc. to Announce First Quarter Financial Results on May 11, 2026April 27, 2026 | globenewswire.comExagen Announces Board Resignation and Committee RestructuringApril 23, 2026 | tipranks.comDoes Exagen (XGN)’s 200%+ Upside Potential Make It One of the Best Penny Stocks Set to Explode?April 12, 2026 | insidermonkey.comHow Analyst Resets Are Reshaping The Exagen (XGN) Investment StoryMarch 27, 2026 | finance.yahoo.comExagen (XGN) price target decreased by 21.78% to 10.03March 27, 2026 | msn.comExagen outlines $70M–$73M 2026 revenue target while expanding sales force and innovation cadenceMarch 11, 2026 | seekingalpha.comExagen Inc. (XGN) Q4 2025 Earnings Call TranscriptMarch 10, 2026 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeEUDA, BDSX, NAKA, and XGN Company DescriptionsBiodesix NASDAQ:BDSX$15.77 +0.96 (+6.48%) As of 01:07 PM Eastern This is a fair market value price provided by Massive. Learn more.Biodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR and NGS, and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.EUDA Health NASDAQ:EUDA$18.38 +0.30 (+1.64%) As of 01:03 PM Eastern This is a fair market value price provided by Massive. Learn more.EUDA Health Holdings Limited operates as a healthcare specialty company. The company operates through two segments, Medical Services and Property Management Services. It offers a range of specialty care services to patients; and operates medical facility general practice clinic that provides holistic care for various illnesses. The company is also involved in the property management that services shopping malls, business office building, or residential apartments. EUDA Health Holdings Limited is headquartered in Singapore.KindlyMD NASDAQ:NAKA$5.39 -0.01 (-0.19%) As of 12:50 PM EasternKindly MD, Inc. (“KindlyMD” or “Kindly”) is a Utah company formed in 2019. KindlyMD is a healthcare data company, focused on holistic pain management and reducing the impact of the opioid epidemic. KindlyMD offers direct health care to patients integrating prescription medicine and behavioral health services to reduce opioid use in the chronic pain patient population. Kindly believes these methods will help prevent and reduce addiction and dependency on opiates. Our specialty outpatient clinical services are offered on a fee-for-service basis. The Company offers evaluation and management, including, but not limited to chronic pain, functional medicine, cognitive behavioral therapy, trauma and addiction therapy, recovery support services, overdose education efforts, peer support, limited urgent care, preventative medicine, medically managed weight loss, and hormone therapy. Through its focus on an embedded model of prescriber and therapist teams, KindlyMD develops patient-specific care programs with a specific mission to reduce opioid use in the patient population while successfully treating patients with effective and evidence-based non-opioid alternatives in close conjunction with behavioral therapy. Beyond its treatment of patients, KindlyMD collects data focused on why and how patients turn to alternative treatments to reduce prescription medication use and addiction. The Company captures all relevant datapoints to assist and appropriately treat each individual patient. This also results in valuable data for the Company and the Company’s investors. We strive to become a source for evidence-based guidelines, data, treatment models, and education in the fight against the opioid crisis in America. Business Revenue Streams We currently earn revenue through (i) patient care services related to medical evaluation and treatment and (ii) product retail sales. Our forecasted plan is to operate across various revenue streams: (i) medical evaluation and treatment visits reimbursed by Medicare, Medicaid, and commercial insurance payers as well as self-pay services, (ii) data collection and research, (iii) education partnerships, (iv) service affiliate agreements, and (v) retail sales. Our principal executive offices are located at 5097 S 900 E, Suite 100 Salt Lake City, UT.Exagen NASDAQ:XGN$5.11 +0.10 (+1.96%) As of 01:08 PM Eastern This is a fair market value price provided by Massive. Learn more.Exagen Inc. develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP test, which identifies RA patients with severe disease. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas If the Market Rally Stalls, This ETF Can Insulate Portfolios Semtech’s Explosive Rally May Only Be Getting Started The Food Delivery War Just Entered Its Final Phase Bath & Body Works Stock Surged Despite Falling Sales—Here’s Why Abercrombie Rallies as Strong Q1 Earnings Extend Winning Streak Dick’s Sporting Goods Isn’t Done Winning Yet Amazon's Alexa for Shopping Strengthens an Already Strong Bull Case TeraWulf Bets on Power Infrastructure to Lead AI Build-Out Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
